FDA Expands Use of Tykerb

(Reuters) UPDATED 2010-02-01

The U.S. Food and Drug Administration has extended the use of the breast cancer drug Tykerb. The drug is approved for use in combination with the drug Femara for hormone positive and HER2-positive breast cancer in post-menopausal women. The approval was based on a study that showed that patients on a combination of the drugs went 35 weeks before a cancer progression compared to 13 weeks for women who got Femara alone.
Read full story >

See all Breast Cancer News

This helped!

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Featuring Content From:

We comply with the HONcode standard for
trustworthy health information: verify here.

By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.

Healthcentral.com is part of Remedy Health Media

FDA Expands Use of Tykerb

People who read this also read...

What the community is saying...

Abraxane: A Better Delivery System for Paclitaxel?

Phyllis Johnson